Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran Inc (BIXT) is a clinical-stage biotechnology company pioneering novel therapies for hypoxia-related conditions and antiviral applications. This page serves as the definitive source for official company announcements, research breakthroughs, and regulatory developments.
Investors and industry professionals will find timely updates on Bioxytran's drug candidates including BXT-25 for stroke-related ischemia and Prolectin-M antiviral research. Our curated news collection features press releases, clinical trial milestones, partnership announcements, and financial disclosures.
All content is verified through primary sources, with emphasis on material developments in the company's AI-driven drug discovery platform and NMR-based molecular analysis. Bookmark this page for streamlined access to critical updates about therapeutic advancements in neurology, wound healing, and viral infection management.
Bioxytran (OTCQB:BIXT) has announced a significant breakthrough in virology, validated in a peer-reviewed journal article. The company's drug candidate, Prolectin-M, has shown effectiveness in stopping COVID-19 and other viruses by blocking galectin, a protein important for viral attachment to cells. This discovery, made using advanced Nuclear Magnetic Resonance (NMR) spectroscopy, could impact both the antiviral and vaccination markets, collectively valued at approximately $147 billion.
The study revealed that galectins, located on the virus's spike protein, are an excellent drug target due to their stability. This could lead to the development of broad-spectrum antivirals effective against various viruses. Bioxytran's CEO, Dr. David Platt, believes this discovery represents a new era in antiviral drug development, potentially revolutionizing the treatment of viral diseases and even chronic illnesses like cancer.
Bioxytran (OTCQB: BIXT) has formed a Joint Venture with the Heme Foundation to develop a Universal Oxygen Carrier (UOC) as an alternative to blood transfusions. The Foundation pledged up to $10 million for the project, with $2 million already invested in prototypes and compound development. Bioxytran retains all intellectual property rights, while the Foundation gains usage rights for blood transfusion applications.
The UOC, a hemoglobin-based oxygen carrier, is designed to be compatible with all blood types, pathogen-free, and shelf-stable at room temperature for 5+ years. It has shown promise in small-scale animal trials and is preparing for a large-scale toxicology study. This technology could revolutionize transfusion medicine, particularly in remote areas with blood supply infrastructure.
Bioxytran's Science Advisor, Prof. Avraham Mayevsky, has published a book titled Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions. The book, available as an eBook or hardcover from Springer, delves into the impact of hyperbaric oxygen on brain functions, particularly mitochondrial activity.
Central to the book is the MDX Viewer, an FDA-approved device that measures tissue oxygenation at the cellular level. The device's output, the Brain Metabolic Score (BMS), is essential for Bioxytran's acellular oxygen carrier (AOC) molecule, BXT-25, which is being developed for ischemic stroke and Alzheimer's disease treatments. Bioxytran aims to use BXT-25 to replace hyperbaric oxygen treatment (HBOT) in clinical trials.
The book offers a comprehensive overview of how hyperbaric oxygen impacts brain biochemical and physiological responses, influencing mitochondrial activity and enhancing brain functions.
FAQ
What is the current stock price of Bioxytran (BIXT)?
What is the market cap of Bioxytran (BIXT)?
